journal
MENU ▼
Read by QxMD icon Read
search

Multiple Sclerosis: Clinical and Laboratory Research

journal
https://www.readbyqxmd.com/read/28524746/a-contemporary-profile-of-primary-progressive-multiple-sclerosis-participants-from-the-narcoms-registry
#1
Amber Salter, Nina P Thomas, Tuula Tyry, Gary R Cutter, Ruth Ann Marrie
BACKGROUND: Primary progressive multiple sclerosis (PPMS) represents 10%-15% of all multiple sclerosis (MS) diagnoses. Information regarding socio-demographic and clinical characteristics of persons with PPMS is limited. OBJECTIVE: To characterize persons with PPMS in the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry. METHODS: We compared demographic and health-related characteristics of NARCOMS Registry participants reporting PPMS in the spring 2015 update survey with those reporting relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS), with characteristics of published PPMS cohorts...
May 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28516805/mesial-temporal-lobe-and-subcortical-grey-matter-volumes-differentially-predict-memory-across-stages-of-multiple-sclerosis
#2
James F Sumowski, Victoria M Leavitt, Maria A Rocca, Matilde Inglese, Gianna Riccitelli, Korhan Buyukturkoglu, Alessandro Meani, Massimo Filippi
BACKGROUND/OBJECTIVE: Memory deficits due to multiple sclerosis (MS) have been variably linked to lower subcortical grey matter (SCGM) and mesial temporal lobe (MTL) volumes. We investigated which is the better predictor and whether this changes across disease stages. METHODS/RESULTS: Memory was assessed in 315 patients. Magnetic resonance imaging (MRI) measured volumes of total brain, grey matter, white matter, MTL (hippocampus, amygdala) and SCGM (thalamus, caudate)...
May 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28516804/spinal-cord-atrophy-as-a-primary-outcome-measure-in-phase-ii-trials-of-progressive-multiple-sclerosis
#3
Niamh Cawley, Carmen Tur, Ferran Prados, Domenico Plantone, Hugh Kearney, Khaled Abdel-Aziz, Sebastian Ourselin, Claudia Am Gandini Wheeler-Kingshott, David H Miller, Alan J Thompson, Olga Ciccarelli
OBJECTIVES: To measure the development of spinal cord (SC) atrophy over 1 year in patients with progressive multiple sclerosis (PMS) and determine the sample sizes required to demonstrate a reduction in spinal cord cross-sectional area (SC-CSA) as an outcome measure in clinical trials. METHODS: In total, 44 PMS patients (26 primary progressive multiple sclerosis (PPMS), 18 secondary progressive multiple sclerosis (SPMS)) and 29 healthy controls (HCs) were studied at baseline and 12 months...
May 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28511578/retinal-atrophy-in-relation-to-visual-functioning-and-vision-related-quality-of-life-in-patients-with-multiple-sclerosis
#4
Lisanne J Balk, Danko Coric, Jenny A Nij Bijvank, Joep Killestein, Bernard Mj Uitdehaag, Axel Petzold
BACKGROUND: Inner retinal layer atrophy in patients with multiple sclerosis (MS) has been validated as a structural imaging biomarker for neurodegeneration. OBJECTIVE: To determine how retinal layer thickness relates to high-contrast visual acuity (HCVA), low-contrast visual acuity (LCVA) and vision-related quality of life (QoL) and to investigate the effect of previous episodes on MS-associated optic neuritis (MSON). METHODS: Spectral-domain optical coherence tomography (SD-OCT) was performed in 267 patients with MS...
May 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28504007/can-we-afford-not-to-prevent-ms-related-disability
#5
Gavin Giovannoni
No abstract text is available yet for this article.
May 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28492101/evaluation-of-2016-magnims-mri-criteria-for-dissemination-in-space-in-patients-with-a-clinically-isolated-syndrome
#6
Jae-Won Hyun, So-Young Huh, Woojun Kim, Min Su Park, Suk-Won Ahn, Joong-Yang Cho, Byung-Jo Kim, Sang-Hyun Lee, Su-Hyun Kim, Ho Jin Kim
OBJECTIVES: We compared validity of 2010 McDonald and newly proposed 2016 Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) criteria for dissemination in space (DIS) in predicting the conversion to clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndrome (CIS). METHODS: Between 2006 and 2016, we enrolled 170 patients who had a first clinical event suggestive of multiple sclerosis (MS) from seven referral hospitals in Korea...
May 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28485678/the-majority-of-natalizumab-treated-ms-patients-have-high-natalizumab-concentrations-at-time-of-re-dosing
#7
Zoé LE van Kempen, Cyra E Leurs, Birgit I Witte, Annick de Vries, Mike P Wattjes, Theo Rispens, Joep Killestein
BACKGROUND: Natalizumab is efficacious in the treatment of relapsing-remitting multiple sclerosis. All patients receive the same treatment regimen of 300 mg every 4 weeks, despite differences in pharmacokinetics between individual patients. OBJECTIVE: To give neurologists insight into natalizumab concentrations at time of re-dosing, we investigated longitudinal natalizumab concentrations in 80 patients in relation to disease activity, with possible influencing factors...
May 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28485659/a-randomized-controlled-trial-to-treat-impaired-learning-and-memory-in-multiple-sclerosis-the-self-gen-trial
#8
Yael Goverover, Nancy Chiaravalloti, Helen Genova, John DeLuca
BACKGROUND: Difficulties in learning and memory are among the most persistent and frequently reported cognitive symptoms in individuals with multiple sclerosis (MS). OBJECTIVE: To examine the efficacy of the self-generation learning program ( self-GEN trial) that consist of behavioral intervention sessions, teaching self-generation technique while using metacognitive strategies to improve learning and memory abilities in persons with MS. Additionally, the treatment aimed to address generalization of the treatment to activities of daily living...
May 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28485186/improved-cognitive-outcomes-in-patients-with-relapsing-remitting-multiple-sclerosis-treated-with-daclizumab-beta-results-from-the-decide-study
#9
Ralph Hb Benedict, Stanley Cohan, Sharon G Lynch, Katherine Riester, Ping Wang, Wanda Castro-Borrero, Jacob Elkins, Guido Sabatella
BACKGROUND: Cognitive impairment is common in multiple sclerosis (MS), with cognitive processing speed being the most frequently affected domain. OBJECTIVE: Examine the effects of daclizumab beta versus intramuscular (IM) interferon (IFN) beta-1a on cognitive processing speed as assessed by Symbol Digit Modalities Test (SDMT). METHODS: In DECIDE, patients with relapsing-remitting multiple sclerosis (RRMS) (age: 18-55 years; Expanded Disability Status Scale (EDSS) score 0-5...
May 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28481191/natalizumab-associated-progressive-multifocal-leukoencephalopathy-is-not-preceded-by-elevated-drug-concentrations
#10
Clemens Warnke, Hans-Peter Hartung
No abstract text is available yet for this article.
May 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28481159/characterization-of-annual-disease-progression-of-multiple-sclerosis-patients-a-population-based-study
#11
Jonatan Freilich, Ali Manouchehrinia, Mark Trusheim, Lynn G Baird, Sophie Desbiens, Ernst Berndt, Jan Hillert
BACKGROUND: Previous research characterizing factors influencing multiple sclerosis (MS) disease progression has typically been based on time to disease milestones (Kaplan-Meier, Cox hazard regression, etc.). A limitation of these methods is the handling of the often large groups of patients not reaching the milestone. OBJECTIVE: To characterize clinical factors influencing MS disease progression as annual transitions from each Expanded Disability Status Scale (EDSS)...
May 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28480798/a-new-role-for-evoked-potentials-in-ms-repurposing-evoked-potentials-as-biomarkers-for-clinical-trials-in-ms
#12
Martin Hardmeier, Letizia Leocani, Peter Fuhr
Evoked potentials (EP) characterize signal conduction in selected tracts of the central nervous system in a quantifiable way. Since alteration of signal conduction is the main mechanism of symptoms and signs in multiple sclerosis (MS), multimodal EP may serve as a representative measure of the functional impairment in MS. Moreover, EP have been shown to be predictive for disease course, and thus might help to select patient groups at high risk of progression for clinical trials. EP can detect deterioration, as well as improvement of impulse propagation, independently from the mechanism causing the change...
May 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28480794/dimethyl-fumarate-induces-changes-in-b-and-t-lymphocyte-function-independent-of-the-effects-on-absolute-lymphocyte-count
#13
Erin E Longbrake, Claudia Cantoni, Salim Chahin, Francesca Cignarella, Anne H Cross, Laura Piccio
BACKGROUND: Dimethyl fumarate (DMF) is used to treat relapsing multiple sclerosis and causes lymphopenia in a subpopulation of treated individuals. Much remains to be learned about how the drug affects B- and T-lymphocytes. OBJECTIVES: To characterize changes in B- and T-cell phenotype and function induced by DMF and to investigate whether low absolute lymphocyte count (ALC) is associated with unique functional changes. METHODS: Peripheral blood mononuclear cells (PBMCs) were collected from DMF-treated patients, untreated patients, and healthy controls...
May 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28474977/pittsburgh-compound-b-pet-white-matter-imaging-and-cognitive-function-in-late-multiple-sclerosis
#14
Burcu Zeydan, Val J Lowe, Christopher G Schwarz, Scott A Przybelski, Nirubol Tosakulwong, Samantha M Zuk, Matthew L Senjem, Jeffrey L Gunter, Rosebud O Roberts, Michelle M Mielke, Eduardo E Benarroch, Moses Rodriguez, Mary M Machulda, Timothy G Lesnick, David S Knopman, Ronald C Petersen, Clifford R Jack, Kejal Kantarci, Orhun H Kantarci
BACKGROUND: There is growing interest in white matter (WM) imaging with positron emission tomography (PET). OBJECTIVES: We studied the association of cognitive function in late multiple sclerosis (MS) with cortical and WM Pittsburgh compound-B PET (PiB-PET) binding. METHODS: In the population-based Mayo Clinic Study of Aging, 24 of 4869 participants had MS (12 underwent PiB-PET). Controls were age and sex matched (5:1). We used automated or semi-automated processing for quantitative image analyses and conditional logistic regression for group differences...
May 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28474969/hla-drb1-04-05-allele-is-associated-with-intracortical-lesions-on-three-dimensional-double-inversion-recovery-images-in-japanese-patients-with-multiple-sclerosis
#15
Koji Shinoda, Takuya Matsushita, Yuri Nakamura, Katsuhisa Masaki, Ryo Yamasaki, Hiroo Yamaguchi, Osamu Togao, Akio Hiwatashi, Jun-Ichi Kira
BACKGROUND: Cortical lesions (CLs) frequently observed in Caucasian patients with multiple sclerosis (MS) contribute to disability. However, it remains unclear whether CLs are associated with clinical features and genetic risk factors, such as HLA-DRB1*15:01 and -DRB1*04:05 in Asian MS patients. OBJECTIVE: To elucidate the frequency of CLs and their association with HLA-DRB1 and DPB1 alleles in Japanese MS patients. METHODS: Three-dimensional double inversion recovery imaging and clinical information were retrospectively obtained from 92 Japanese MS patients...
May 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28463075/stop-inflammation-and-you-stop-neurodegeneration-in-ms-yes
#16
Heather Yf Yong, V Wee Yong
No abstract text is available yet for this article.
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28463074/stop-inflammation-and-you-stop-neurodegeneration-in-ms-commentary
#17
Reinhard Hohlfeld
No abstract text is available yet for this article.
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28463073/stop-inflammation-and-you-stop-neurodegeneration-in-ms-no
#18
Tomas Kalincik
No abstract text is available yet for this article.
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28445084/brain-atrophy-15-years-after-cis-baseline-and-follow-up-clinico-radiological-correlations
#19
Angela Vidal-Jordana, Jaume Sastre-Garriga, Deborah Pareto, Carmen Tur, Georgina Arrambide, Susana Otero-Romero, Elena Huerga, Raquel Mitjana, Cristina Auger, Mar Tintoré, Alex Rovira, Xavier Montalban
BACKGROUND: Brain atrophy in multiple sclerosis (MS) patients is present since the very early stages of the disease and it has been related to long-term disability. OBJECTIVE: To estimate brain volume (BV) at 15 years after a clinically isolated syndrome (CIS) and to evaluate its relationship with disease outcomes. METHODS: From a prospective cohort including patients presenting with a CIS, 54 patients with a brain magnetic resonance imaging (MRI) performed 15 years after CIS were included...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28445083/fatigue-and-physical-functioning-in-children-with-multiple-sclerosis-and-acute-disseminated-encephalomyelitis
#20
Leontien Cc Toussaint-Duyster, Yu Yi M Wong, Monique Hm Van der Cammen-van Zijp, Daniëlle Van Pelt-Gravesteijn, Coriene E Catsman-Berrevoets, Rogier Q Hintzen, Rinze F Neuteboom
BACKGROUND AND OBJECTIVE: Fatigue and physical impairments are a major concern in children with multiple sclerosis (MS) and after acute disseminated encephalomyelitis (post-ADEM). We here aimed to evaluate the interaction between fatigue, exercise capacity, motor performance, neurological status, and quality of life (HRQoL). METHODS: In this cross-sectional study, data of 38 children (MS n = 22, post-ADEM n = 16), aged 4-17 years attending our national pediatric MS center, were studied...
April 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
journal
journal
32305
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"